Safety of Infliximab and Other Biologic Agents in the Inflammatory Bowel Diseases

Jagadeshwar G. Reddy; Edward V. Loftus

doi:10.1016/j.gtc.2006.09.008

Safety of Infliximab and Other Biologic Agents in the Inflammatory Bowel Diseases

Jagadeshwar G. Reddy, Edward V. Loftus

Gastroenterology and Hepatology

Research output: Contribution to journal › Review article › peer-review

72 Scopus citations

Abstract

In many ways, infliximab has drastically altered expectations for medical therapy in IBD, and it is expected that adalimumab and certolizumab pegol will ultimately have a similar role. Patients initiating such therapy should be made cognizant of the potential risks of serious infection including opportunistic ones, such as TB and histoplasmosis; demyelinating disorders; CHF; and lymphoma. Proper selection of candidates for anti-TNF-α therapy is critical in maintaining a proper benefit-to-risk ratio.

Original language	English (US)
Pages (from-to)	837-855
Number of pages	19
Journal	Gastroenterology Clinics of North America
Volume	35
Issue number	4
DOIs	https://doi.org/10.1016/j.gtc.2006.09.008
State	Published - Dec 1 2006

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.1016/j.gtc.2006.09.008

Fingerprint Dive into the research topics of 'Safety of Infliximab and Other Biologic Agents in the Inflammatory Bowel Diseases'. Together they form a unique fingerprint.

Cite this

@article{2d342a83e2ee471c8bc058db38306fd5,

title = "Safety of Infliximab and Other Biologic Agents in the Inflammatory Bowel Diseases",

abstract = "In many ways, infliximab has drastically altered expectations for medical therapy in IBD, and it is expected that adalimumab and certolizumab pegol will ultimately have a similar role. Patients initiating such therapy should be made cognizant of the potential risks of serious infection including opportunistic ones, such as TB and histoplasmosis; demyelinating disorders; CHF; and lymphoma. Proper selection of candidates for anti-TNF-α therapy is critical in maintaining a proper benefit-to-risk ratio.",

author = "Reddy, {Jagadeshwar G.} and Loftus, {Edward V.}",

year = "2006",

month = dec,

day = "1",

doi = "10.1016/j.gtc.2006.09.008",

language = "English (US)",

volume = "35",

pages = "837--855",

journal = "Gastroenterology Clinics of North America",

issn = "0889-8553",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Safety of Infliximab and Other Biologic Agents in the Inflammatory Bowel Diseases

AU - Reddy, Jagadeshwar G.

AU - Loftus, Edward V.

PY - 2006/12/1

Y1 - 2006/12/1

N2 - In many ways, infliximab has drastically altered expectations for medical therapy in IBD, and it is expected that adalimumab and certolizumab pegol will ultimately have a similar role. Patients initiating such therapy should be made cognizant of the potential risks of serious infection including opportunistic ones, such as TB and histoplasmosis; demyelinating disorders; CHF; and lymphoma. Proper selection of candidates for anti-TNF-α therapy is critical in maintaining a proper benefit-to-risk ratio.

AB - In many ways, infliximab has drastically altered expectations for medical therapy in IBD, and it is expected that adalimumab and certolizumab pegol will ultimately have a similar role. Patients initiating such therapy should be made cognizant of the potential risks of serious infection including opportunistic ones, such as TB and histoplasmosis; demyelinating disorders; CHF; and lymphoma. Proper selection of candidates for anti-TNF-α therapy is critical in maintaining a proper benefit-to-risk ratio.

UR - http://www.scopus.com/inward/record.url?scp=33751334334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751334334&partnerID=8YFLogxK

U2 - 10.1016/j.gtc.2006.09.008

DO - 10.1016/j.gtc.2006.09.008

M3 - Review article

C2 - 17129816

AN - SCOPUS:33751334334

VL - 35

SP - 837

EP - 855

JO - Gastroenterology Clinics of North America

JF - Gastroenterology Clinics of North America

SN - 0889-8553

IS - 4

ER -